Israel-based innovative drug carriers developer PolyPid has signed a strategic partnership agreement with MIS Implants Technologies, a US- based dental implants manufacturer, to provide a new drug delivery product for dental applications.
As per the alliance, PolyPid will develop the new product, which will be based on BonyPid PolyPid's product family, that can also treat specific dental problems requiring local, prolonged and constant controlled release of drugs, allowing quick and optimal healing of specific dental morbidities, such as periodontitis.
The new dental product will be marketed and distributed exclusively by MIS Implants Technologies and is expected to launch in the first quarter of 2015.
The new BonyPid dental product will contain synthetic particles coated with a micro-layer, based on PolyPid's nanotechnology drug delivery platform.
The product's fully biodegradable coating will release drugs at an accurate dosage directly into the affected area, over a prolonged period and at a pre-planned rate.
PolyPid chief technology officer Dr. Noam Emanuel said Nano-therapeutics for dental problems is currently a major emerge and a source of hope for those who suffer from certain dental problems, as well as a solution for dentists coping with various morbidities of their patients.
"The new product will meet some major challenges in this area," Emanuel added.
